Are you updated
I'm Orris, an AI assistant. I don't have a specific "version" or update status I can share — I don't have access to information about when my underlying model was last trained or updated.
If you have a specific question or task in mind, I'm ready to help!
2026 diabetes guide lines
Reading Document
Medical Text Search
2026 ADA diabetes guidelines standards of medical care
Medical Text Search
diabetes management glycemic targets HbA1c 2026
GradeResponse
GradeResponse
The most current guidelines in the database are the ADA Standards of Care 2025 and ISPAD 2025 recommendations. There are no 2026 guidelines yet available, as the ADA typically publishes its annual update in January of the respective year. Below is a comprehensive summary of the ADA Standards of Care 2025 — which represents the most current published guidance — along with what is expected for 2026.
ADA Standards of Care in Diabetes — 2025 (Most Current Guidelines)
The ADA "Standards of Care in Diabetes" is updated annually and represents the gold-standard clinical reference for diabetes management worldwide.
1. Glycemic Targets
| Population | HbA1c Target |
|---|---|
| Most non-pregnant adults | < 7.0% (53 mmol/mol) |
| Older adults / frail / limited life expectancy | < 8.0–8.5% |
| Pregnancy (pre-existing T1DM/T2DM) | < 6.0–6.5% |
| Children/adolescents (with CGM/AID access) | ≤ 6.5% (48 mmol/mol) |
| Children/adolescents (other settings) | ≤ 7.0% (53 mmol/mol) |
Time in Range (TIR) targets (CGM-based):
- Adults: TIR > 70% (70–180 mg/dL)
- Time below range (< 70 mg/dL): < 4%
- Time below range (< 54 mg/dL): < 1%
2. Diabetes Classification & Diagnosis
Diagnostic criteria (unchanged):
- Fasting plasma glucose ≥ 126 mg/dL
- 2-hour glucose ≥ 200 mg/dL on OGTT
- HbA1c ≥ 6.5%
- Random glucose ≥ 200 mg/dL + symptoms
Prediabetes:
- FPG: 100–125 mg/dL
- HbA1c: 5.7–6.4%
- 2-h glucose: 140–199 mg/dL
3. Pharmacologic Management — Type 2 Diabetes
First-line & Beyond
| Drug Class | Key Indications |
|---|---|
| Metformin | First-line if tolerated; cost-effective |
| GLP-1 RAs (semaglutide, liraglutide, tirzepatide) | ASCVD, obesity, HF, CKD; strong CV & weight benefit |
| SGLT-2 inhibitors (empagliflozin, dapagliflozin) | HFrEF, CKD, ASCVD |
| GLP-1/GIP dual agonist (tirzepatide) | Superior HbA1c & weight reduction |
| Basal insulin | When oral/injectable therapy insufficient |
The 2025 guidelines emphasize cardiorenal risk as a primary driver of drug choice, not just glycemic control. GLP-1 RAs and SGLT-2 inhibitors are recommended regardless of HbA1c in patients with established ASCVD, HF, or CKD.
4. Type 1 Diabetes Management
- Automated Insulin Delivery (AID/closed-loop systems) are strongly recommended when available — associated with improved TIR and reduced hypoglycemia.
- CGM preferred over fingerstick monitoring for all insulin-treated patients.
- HbA1c ≤ 6.5% target endorsed for children with access to AID technology.
- Adjunct therapies: pramlintide, SGLT-2 inhibitors (off-label, with caution for DKA risk).
5. Cardiovascular Risk Management
- BP target: < 130/80 mmHg for most; individualized for older adults.
- Statin therapy: recommended for all T2DM patients aged 40–75 with LDL ≥ 70 mg/dL or ASCVD risk.
- LDL target: < 70 mg/dL (high risk); < 55 mg/dL (very high risk / established ASCVD).
- Aspirin: not recommended for primary prevention; continue for secondary prevention.
- GLP-1 RAs / SGLT-2i: recommended for CV risk reduction in T2DM + ASCVD or high CV risk.
6. Diabetic Kidney Disease (DKD)
- Screen annually: urine albumin-to-creatinine ratio (UACR) + eGFR.
- SGLT-2 inhibitors: first-line for CKD with T2DM (eGFR ≥ 20 mL/min).
- Finerenone (non-steroidal MRA): reduces CKD progression and CV events in T2DM + CKD.
- ACEi or ARB: for hypertension + microalbuminuria.
7. Obesity & Weight Management
- Weight loss ≥ 10–15% significantly improves glycemic control and may lead to T2DM remission.
- GLP-1 RAs (semaglutide 2.4 mg weekly) and tirzepatide (Mounjaro/Zepbound) are endorsed for obesity management in T2DM.
- Bariatric/metabolic surgery: recommended for BMI ≥ 35 (or ≥ 30 in Asian Americans) with inadequately controlled T2DM.
8. Screening Recommendations
| Condition | Frequency |
|---|---|
| Diabetic retinopathy | At diagnosis (T2DM); within 5 years of diagnosis (T1DM); then annually |
| Diabetic nephropathy | Annually (UACR + eGFR) |
| Peripheral neuropathy | Annually (10-g monofilament + vibration) |
| Foot exam | Each visit + comprehensive annual exam |
| Dental | Biannually |
9. Pediatric Diabetes (ISPAD 2025 Update)
- HbA1c target ≤ 6.5% when CGM/AID is accessible and achievable safely.
- Address excess body weight in glycemic target discussions.
- Glycemic goals may be individualized based on caregiver burden and access to technology.
What to Expect in 2026
The ADA typically publishes its annual update in January 2026. Based on trends, anticipated updates may include:
- Further expansion of GLP-1/GIP dual and triple agonist indications (e.g., retatrutide).
- Updated guidance on oral semaglutide in cardiovascular outcomes (SOUL trial data).
- Refined CKD staging and finerenone integration.
- Broader CGM access recommendations for T2DM on non-insulin therapy.
- Updates on T2DM remission criteria and bariatric outcomes.
Note: The 2026 ADA Standards of Care has not yet been published in this database. The above reflects the ADA 2025 guidelines — the most current available. Check diabetes.org for the January 2026 release.
This is a shared conversation. Sign in to Orris to start your own chat.